Skip to main content

Mylan Pharmaceuticals Inc. v. Acorda Therapeutics Inc.

Certiorari Denied

Petition for certiorari denied on January 9, 1917.

Docket No.16-360
Op. BelowFed. Cir.
SCOTUS Page

Issue

Whether the mere filing of an abbreviated new drug application by a generic pharmaceutical manufacturer is sufficient to subject the manufacturer to specific personal jurisdiction in any state where it might someday market the drug.

Proceedings & orders timeline

Sep 19, 2016
Petition for a writ of certiorari filed. (Response due October 21, 2016)
Oct 4, 2016
Consent to the filing of amicus curiae briefs, in support of either party or of neither party, received from counsel for the respondents Acorda Therapeutics, Inc., and Pharma Ireland Limited.
Oct 6, 2016
Order extending time to file response to petition to and including November 21, 2016, for all respondents.
Oct 21, 2016
Brief amicus curiae of Generic Pharmaceutical Association filed.
Nov 21, 2016
Brief of respondent AstraZeneca AB in opposition filed.
Nov 21, 2016
Brief of respondents Acorda Therapeutics, Inc. and Alkermes Pharma Ireland Limited in opposition filed.
Dec 7, 2016
DISTRIBUTED for Conference of January 6, 2017.
Dec 7, 2016
Reply of petitioners Mylan Pharmaceuticals, et al. filed. (Distributed)
Dec 12, 2016
Rescheduled.
Dec 21, 2016
DISTRIBUTED for Conference of January 6, 2017.
Jan 9, 2017
Petition DENIED. Justice Alito took no part in the consideration or decision of this petition.

Welcome to SCOTUSblog

Tell us a bit about yourself so we can tailor what you see. You can update these any time in your account.